Helix BioPharma Corp. (HBP) - Cash Flow Conversion Efficiency

Latest as of January 2026: -0.030x

Based on the latest financial reports, Helix BioPharma Corp. (HBP) has a cash flow conversion efficiency ratio of -0.030x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-456.00K ≈ $-329.86K USD) by net assets (CA$15.36 Million ≈ $11.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Helix BioPharma Corp. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Helix BioPharma Corp. - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Helix BioPharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Helix BioPharma Corp. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Helix BioPharma Corp. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
LTR Pharma Ltd AU:LTP	-0.089x
XBP Europe Holdings Inc NASDAQ:XBP	-1.147x
Borges Agricultural & Industrial Nuts S.A. MC:BAIN	0.004x
Daedong Gear Co. Ltd KQ:008830	0.067x
Tacheng Real Estate Co Ltd TWO:6171	-0.098x
Y-Entec Co. Ltd KQ:067900	0.018x
Thac Ba Hydropower JSC VN:TBC	0.057x
Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme AT:MOTO	-0.109x

Annual Cash Flow Conversion Efficiency for Helix BioPharma Corp. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Helix BioPharma Corp. from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see HBP market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-07-31	CA$15.59 Million ≈ $11.27 Million	CA$-3.83 Million ≈ $-2.77 Million	-0.246x	-100.42%
2024-07-31	CA$-90.00K ≈ $-65.10K	CA$-5.22 Million ≈ $-3.78 Million	57.989x	+785.52%
2023-07-31	CA$-844.00K ≈ $-610.54K	CA$-5.53 Million ≈ $-4.00 Million	6.549x	+132.09%
2022-07-31	CA$319.00K ≈ $230.76K	CA$-6.51 Million ≈ $-4.71 Million	-20.404x	-405.50%
2021-07-31	CA$-1.39 Million ≈ $-1.01 Million	CA$-9.30 Million ≈ $-6.73 Million	6.679x	+283.91%
2020-07-31	CA$2.98 Million ≈ $2.16 Million	CA$-10.83 Million ≈ $-7.83 Million	-3.632x	-315.43%
2019-07-31	CA$-3.28 Million ≈ $-2.37 Million	CA$-5.53 Million ≈ $-4.00 Million	1.686x	-65.79%
2018-07-31	CA$-1.53 Million ≈ $-1.10 Million	CA$-7.52 Million ≈ $-5.44 Million	4.927x	-99.10%
2017-07-31	CA$-17.00K ≈ $-12.30K	CA$-9.29 Million ≈ $-6.72 Million	546.765x	+19640.99%
2016-07-31	CA$3.16 Million ≈ $2.29 Million	CA$-8.85 Million ≈ $-6.40 Million	-2.798x	-125.05%
2015-07-31	CA$6.83 Million ≈ $4.94 Million	CA$-8.49 Million ≈ $-6.14 Million	-1.243x	-10.09%
2014-07-31	CA$6.81 Million ≈ $4.93 Million	CA$-7.69 Million ≈ $-5.56 Million	-1.129x	+28.89%
2013-07-31	CA$4.92 Million ≈ $3.56 Million	CA$-7.81 Million ≈ $-5.65 Million	-1.588x	+29.95%
2012-07-31	CA$6.22 Million ≈ $4.50 Million	CA$-14.11 Million ≈ $-10.21 Million	-2.267x	-384.94%
2011-07-31	CA$22.11 Million ≈ $16.00 Million	CA$-10.34 Million ≈ $-7.48 Million	-0.468x	+39.56%
2010-07-31	CA$15.76 Million ≈ $11.40 Million	CA$-12.19 Million ≈ $-8.82 Million	-0.774x	-0.33%
2009-07-31	CA$17.06 Million ≈ $12.34 Million	CA$-13.16 Million ≈ $-9.52 Million	-0.771x	-126.16%
2008-07-31	CA$20.52 Million ≈ $14.85 Million	CA$-7.00 Million ≈ $-5.06 Million	-0.341x	+28.58%
2007-07-31	CA$12.73 Million ≈ $9.21 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.477x	--

About Helix BioPharma Corp.

TO:HBP Canada Biotechnology

Market Cap

$78.46 Million

CA$108.46 Million CAD

Market Cap Rank

#20242 Global

#695 in Canada

Share Price

CA$1.42

Change (1 day)

-4.70%

52-Week Range

CA$0.90 - CA$5.31

All Time High

CA$11.25